Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Undisclosed information: How MiRNA-29b increases the expression of tumor suppressor AIM2.
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
A recent study from the Department of Immunology, St. Jude Children’s Research Hospital, Memphis, TN 38105, USA shows that: “Critical Role for the DNA Sensor AIM2 in Stem Cell Proliferation and Cancer”. This study was published in the 17 June 2015 issue of the journal “Cell” (the number 1 research journal in “General biology” with an Impact factor of 33.16) by Prof. Thirumala Devi Kanneganti, Si Ming Man and others.
On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Natural product-based therapy for Colorectal cancer: MiRNA-29b increases the expression of DNA Sensor AIM2 and inhibits expansion of tumor-initiating intestinal stem cell population via up regulation of its target gene
Given that (1) more than 1 million people every year worldwide are affected by Intestinal cancer; (2) the number of deaths has had increased from 490,000 in 1990 to 715,000 in 2010; (3) Intestinal cancer is the second and third most frequent cause of cancer in women and men, respectively; (4) Intestinal cancer is more common in developed countries than in developing countries; and (5) the global economic cost spent for Intestinal cancer treatment is enormous, there is an urgent need to find: (1) a cheaper alternative to the existing expensive drugs; and (2) a Natural product-based side-effect-free drug.
A number of studies suggests that immune sensor Absent in Melanoma 2 (AIM2) is mutated in colorectal cancer. However, the significance of which is far from clear. Prof. Thirumala Devi Kanneganti’s research team has recently shown that AIM2 protects against colorectal cancer via inhibition of tumor-initiating intestinal stem cell proliferation.
This study suggests that MiRNA-29b, by decreasing the expression of its target gene, it may increase the expression of tumor suppressor AIM2. Thereby, it may: (1) inhibit uncontrolled proliferation of tumor-initiating intestinal stem cells; (2) decrease the population of dysbiotic gut microbiota; and (3) prevent colorectal cancer. Thus, pharmacological formulations encompassing “MiRNA-29b activators“ may be used to inhibit the progression of colorectal cancer.
* Research cooperation
Citation: Boominathan, L., Natural product-based therapy for Colorectal cancer: MiRNA-29b increases the expression of DNA Sensor AIM2 and inhibits expansion of tumor-initiating intestinal stem cell population via up regulation of its target gene, 7/October/2015, 10.54 pm, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite drop us a line at email@example.com